<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82184">
  <stage>Registered</stage>
  <submitdate>1/08/2007</submitdate>
  <approvaldate>6/08/2007</approvaldate>
  <actrnumber>ACTRN12607000403437</actrnumber>
  <trial_identification>
    <studytitle>Effect of pump prime on bicarbonate, unmeasured ions, and acid-base balance during and after cardiopulmonary bypass</studytitle>
    <scientifictitle>Effect of pump prime on bicarbonate, unmeasured ions, and acid-base balance during and after cardiopulmonary bypass</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Acid-base disorders</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients randomized to cardiopulmonary bypass primed with either 1500ml of Ringers Injection(Baxter, Sydney Australia):  sodium 144 mmol/L, potassium 4 mmol/L , calcium 2 mmol/L , and chloride 152 mmol/L; OR 1500ml of Hartmanns solution (Baxter, Sydney, Australia): sodium 129 mmol/L, potassium 5 mmol/L, calcium 2 mmol/L , chloride 109 mmol/L, and lactate 29 mmol/L .  

Patients will recieve one dose only of either the Ringer's Injection prime or Hartmann's prime when cardiopulmonary bypass is initiated.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The base-excess will be measured in arterial blood sampled before bypass and then 2, 5, 10, 15 and 30 minutes after initiating bypass; and then 5 minutes after ceasing bypass and on arrival in Intensive Care. The difference between the grand means of base-excess will be compared between the Ringer's Injection and Hartmann's groups.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma electrolyte levels will be measured in arterial blood sampled before bypass and then 2, 5, 10, 15 and 30 minutes after initiating bypass; and then 5 minutes after ceasing bypass and on arrival in Intensive Care. The difference between the grand means of the electrolytes will be compared between the Ringer's Injection and Hartmann's groups.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults undergoing elective primary coronary artery bypass surgery.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patient declines, age less than 18 years, age greater than 75 years, creatinine concentration greater than 150 micromoles/L, diabetes mellitus, anaemia (hemoglobin level &lt;100g/L), pre-existing acid-base abnormalities, and extremes in weight (body weight &lt;50kg or &gt;100kg.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All eligible patients approached prior to surgery. Allocation from opaque envelopes on day of surgery.</concealment>
    <sequence>Random number table from hospital pharmacy</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Blinding: (subjects) patients; (clinicans) anaesthetists, medical perfusionists, surgeons.</designfeatures>
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/12/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Associate Professor David Story
Austin Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Department of Anaesthesia
Austin Health</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Australian and New Zealand College of Anaesthetists (ANZCA)</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Frank Liskaser</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Study hypothesis: That priming the cardiopulmonary bypass pump with Hartmann's solution rather than Ringer's Injection will decrease the amount of acidosis associated with cardiopulmonary bypass.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor David Story</name>
      <address>Department of Anaesthesia
Austin Hospital
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94963800</phone>
      <fax>+61 3 94596421</fax>
      <email>David.Story@austin.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Associate Professor David Story</name>
      <address>Department of Anaesthesia
Austin Hospital
Studley Rd
Heidelberg VIC 3084</address>
      <phone>+61 3 94963800</phone>
      <fax>+61 3 94596421</fax>
      <email>David.Story@austin.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>